Chanda Anderson
Family · Norfolk, NENPI 1508401548
Payments from drug & device makers
Across 224 payments — averaging $15.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$875
- AstraZeneca$451
- Pfizer$267
- Amgen$175
- Novo Nordisk$153
- Nestle Healthcare Nutrition Inc.$136
- plus $1K from 34 others
What the payments were for
- Food & beverage$3,474100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 66 | $875 |
| AstraZeneca | 20 | $451 |
| Pfizer | 20 | $267 |
| Amgen | 14 | $175 |
| Novo Nordisk | 10 | $153 |
| Nestle Healthcare Nutrition Inc. | 2 | $136 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $130 |
| Amarin Pharma, Inc. | 10 | $125 |
| Otsuka America Pharmaceutical, Inc. | 8 | $124 |
| Lilly USA, LLC | 7 | $96 |
| Merck | 6 | $91 |
| Daiichi Sankyo Inc. | 6 | $87 |
| Bayer | 4 | $60 |
| E.r. Squibb & Sons, L.L.C. | 4 | $55 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $52 |
| Xeris Pharmaceuticals, Inc. | 3 | $50 |
| Biohaven Pharmaceuticals, Inc. | 2 | $50 |
| Mayne Pharma Commercial LLC | 3 | $43 |
| Vanda Pharmaceuticals Inc. | 2 | $43 |
| Novartis | 2 | $42 |
| Lundbeck LLC | 2 | $36 |
| Biogen | 2 | $33 |
| Astellas Pharma US Inc | 2 | $29 |
| Boehringer Ingelheim | 2 | $28 |
| GSK | 2 | $23 |
| Boston Scientific | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Insulet Corporation | 1 | $14 |
| Sanofi | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Convatec Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Seqirus USA Inc | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,474 in reported general payments places this provider in the 90th percentile of 809 family providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 44 | $40,927 |
| OzempicSemaglutide | 43 | $37,394 |
| EliquisApixaban | 42 | $30,146 |
| JardianceEmpagliflozin | 33 | $29,910 |
| MounjaroTirzepatide | 30 | $28,960 |
| RybelsusSemaglutide | 21 | $25,663 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $16,275 |
| FarxigaDapagliflozin Propanediol | 13 | $15,806 |
| JanuviaSitagliptin Phosphate | 13 | $10,325 |
| MyrbetriqMirabegron | 15 | $10,221 |
| Repatha SureclickEvolocumab | 17 | $9,526 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,407 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,375 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $3,520 |
| Levothyroxine Sodium | 312 | $2,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $96 | $69,88774 claims |
| Novo NordiskOzempic, Rybelsus | $153 | $63,05764 claims |
| PfizerEliquis | $267 | $30,14642 claims |
| Boehringer IngelheimJardiance | $28 | $29,91033 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $23 | $22,65036 claims |
| AstraZenecaFarxiga, Symbicort | $451 | $19,32629 claims |
| MerckJanuvia | $91 | $10,32513 claims |
| Astellas Pharma US IncMyrbetriq | $29 | $10,22115 claims |
| AbbVieSynthroid | $875 | $74720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 809 family providers in Nebraska.
Other family in Norfolk
- Michelle BrtekzwienerNorfolk$59K
- Chantel CollierFriend$257K
- Stephanie SimonOmaha$157K
- Rebecca NewberryOmaha$156K
- Angela CraigOmaha$35K
- Laura FalconeOmaha$26K
- Ladeana SmedlundBoys Town$21K
- Brittany MatneyOmaha$14K
- Patricia TeeterWahoo$13K
- Mary MetzLincoln$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.